Objective To review the eradication rate for Helicobacter Pylori (H. pylori) eradication therapy with Ranitidine bismuth citrate (RBC). Methods A systematic review of all the relevant randomized controlled trials (RCTs) was performed according to International Cochrane Collaboration. Data Source RCTs were identified from specialized trials register of Cochrane U GDP Group, the Cochrane library, additional electronic search (including MEDLINE and CBM), handsearching, and personal contact with pharmaceutical companies. Data Selection Randomized clinical trials comparing RBC or RBC in combination with other antibiotics such as proton pump inhibitor, H2-receptor antagonist, other bismuth or placebo were included. No language and blinding limitations were applied. Inclusion criteria Data were extracted independently by two reviewers. The methodological quality of trials was assessed by the Jadad-scale plus allocation concealment. Statistics analysis was managed by using RevMan 4. 1. Results Fifteen randomized clinical trials including 3 638 patients were included, with eight trials of high methodological quality. Meta-analysis indicated that odds ratio was 3.06 (95%CI 2.62 to 3. 58, P lt; 0. 000 01) comparing RBC to controls. But the heterogeneity was significant (P lt; 0. 000 01), so we choose random effects model. Then the odds ratio was 2.05 (95%CI 1. 29 to 3. 25, P=0.002). No serious adverse effects were found. Sensitivity analysis showed that the specimens and the quality of RCT haven’t affected researching result. Conclusion RBC is more effective in Helicobacter Pylori eradication therapy than others.
目的:雷尼替丁三联疗法与奥美拉唑三联疗法治疗消化性溃疡的疗效比较。方法:将73例消化性溃疡随机分为两组。治疗组:37例,雷尼替丁150 mg、阿莫西林1 000 mg、甲硝唑400 mg每日2次,治疗2周后,单用雷尼替丁150 mg连用4周。对照组:36例,奥美拉唑20 mg、阿莫西林1 000 mg、甲硝唑400 mg每日2次口服。治疗2周后,单用奥美拉唑20 mg连用4周。治疗期间每周到门诊随访,记录临床症状改善情况。用药结束后1月做胃镜检查。结果:治疗后两组的临床症状改善或消失。胃镜复查结果无统计学差异。结论:治疗组和对照组的疗效相同。